Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 3/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262370 | 1.00 | MME (0.56) | MMESLC1A3SLC1A2CPA1CACNA2D1 | |
| SCHEMBL307076 | 1.00 | MME (0.56) | MMESLC1A3SLC1A2CPA1CACNA2D1 | |
| SCHEMBL14591440 | 0.87 | FOLH1 (0.62) | MMECPA1FOLH1ADRA1ACPB1 | |
| SCHEMBL524140 | 0.87 | FOLH1 (0.62) | MMECPA1FOLH1ADRA1ACPB1 | |
| Hydrochloric Acid SCHEMBL8841246 | 0.84 | FOLH1 (0.59) | MMECPA1FOLH1ADRA1ACPB1 | |
| SCHEMBL270456 | 0.84 | FOLH1 (0.67) | MMECPA1FOLH1CPB1CPA3 | |
| SCHEMBL276879 | 0.84 | SLC1A3 (0.73) | MMESLC1A3SLC1A2CPA1ADRA1A | |
| SCHEMBL10000266 | 0.83 | MME (0.55) | MMESLC1A3SLC1A2CPA1CACNA2D1 | |
| SCHEMBL129650 | 0.83 | FOLH1 (0.48) | MMECPA1FOLH1CPB1CPA3 | |
| SCHEMBL25762254 | 0.83 | SLC1A3 (0.54) | MMESLC1A3SLC1A2CPA1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| EP-0839798-B1 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LAB (US) | 2005-08-17 | — | — | EP | disclosed |
| CN-1205181-C | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUOTS LT (DK) | 2005-06-08 | — | — | CN | disclosed |
| CN-1161331-C | Hydrazine derivative | - | 2004-08-11 | — | — | CN | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| CN-1148346-C | Hydrazine derivative | - | 2004-05-05 | — | — | CN | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| CN-1309634-A | Hydrazine derivs. | HOFFMANN LA ROCHE (CH) | 2001-08-22 | — | — | CN | disclosed |
| CN-1066150-C | Bridged indoles as matrix metalloprotease inhibitors | SYNTEX INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5538950-A | PEPTIDE DERIVATIVES AS HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0621867-A1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-5300501-A | Metalloproteinase inhibitors | CELLTECH LIMITED (GB) | 1994-04-05 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| WO-1993010144-A1 | NEW ENDOTHELIN ANTAGONISTS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-27 | — | — | WO | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | MME 106/4885SLC1A3 4132/4885SLC1A2 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.